PROCEED + DETECT Year 9 supplement patient care costs

继续检测 9 年级补充患者护理费用

• 批准号: 10887986
• 负责人: Kenneth Cusi
• 金额: $ 13.5万
• 依托单位: UNIVERSITY OF FLORIDA
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-28 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10887986
• 关键词: Acute; Address; Adult; Ancillary Study; Biological; Biological Markers; Biological Specimen Banks; Blood; Cancer Research Project; Child; Childhood; Clinical; Clinical Management; Clinical Research; Clinical Trials; Collaborations; Collection; Complex; Diabetes Mellitus; Diagnosis; Disease; Duodenum; Early Diagnosis; Educational workshop; Exocrine pancreatic insufficiency; Feces; Fostering; Functional disorder; Future; Goals; Juice; Malignant neoplasm of pancreas; Methods; Natural History; Non-Insulin-Dependent Diabetes Mellitus; Pancreas; Pancreatic Diseases; Pancreatitis; Pathogenesis; Pathogenicity; Patient Care; Patients; Pediatric cohort; Phenotype; Prevention; Protocols documentation; Recurrence; Relapse; Research; Resources; Saliva; Sampling; Strategic Planning; Structure; Therapeutic; Time; Tissues; Translational Research; United States National Institutes of Health; Urine; Work; acute pancreatitis; biomarker validation; care costs; chronic pain; chronic pancreatitis; cohort; improved; prospective; radiological imaging; recruit; risk stratification; specific biomarkers; working group

Summary/Abstract The Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) was formed as a consequence of several NIH-sponsored workshops focused on defining important research goals for improving care of patients with pancreatic diseases. The goals of the CPDPC have been to investigate the clinically important inter-relationships between pancreatitis, diabetes, and pancreatic cancer, focused on better understanding mechanisms, pathophysiology, and natural history, on improving early diagnosis, discovering specific biomarkers, and ultimately serving as a platform for exploratory and subsequent larger-scale clinical trials. The CPDPC undertook these efforts through the establishment of several prospective patient cohorts, coordinated and planned through the formation of several working groups. These working groups (WGs) include the CP Adult WG, CP Pediatric WG, DM PDAC WG, and the Type3C DM WG. The PROCEED cohort, organized by the CP Adult WG, will ultimately include 1600 adult subjects, and is focused on patients with acute, acute relapsing, and chronic pancreatitis. The INSPIRRE 2 cohort, organized by the CP Pediatric WG, will be comprised of 860 children with acute relapsing and chronic pancreatitis. The DETECT cohort, organized by the Type3C DM WG, is recruiting subjects with typical Type 2 diabetes mellitus as well as patients with diabetes due to pancreatic cancer or chronic pancreatitis, to determine mechanistic differences between these types of diabetes and leverage that information for biomarker and therapeutic benefit. Each cohort will represent a large sample of deeply phenotyped and characterized subjects, with comprehensive annotated biospecimen (biologic samples, radiographic) collection, who are being followed over time. These cohorts, when fully recruited and followed-up, provide a unique and powerful resource to address many unanswered clinical questions and to address the goals of the CPDPC charter. The CPDPC is organized to allow numerous ancillary studies to proceed in parallel to the main cohort recruitment, and these ancillary studies now number more than 50. These ancillary studies have helped inform the work of the CPDPC, and established a set of methods and protocols to guide the consortium, as well as provide defined methods and definitions for future clinical research in these diseases. The structure of the CPDPC provides an unparalleled opportunity for internal and external collaboration to foster clinical studies and develop more effective prediction, prevention, and treatment of complex pancreatic diseases.

摘要/摘要 慢性胰腺炎、糖尿病和胰腺癌研究联盟 (CPDPC) 的成立是 NIH 主办的多个研讨会的结果，重点关注 确定改善胰腺疾病患者护理的重要研究目标。这 CPDPC 的目标是调查临床上重要的相互关系 胰腺炎、糖尿病和胰腺癌，重点是更好地了解机制， 病理生理学和自然史，改善早期诊断，发现特异性 生物标志物，并最终作为探索性和后续更大规模的平台 临床试验。 CPDPC 通过设立多个机构来开展这些工作 通过形成几个工作组来协调和规划前瞻性患者队列 组。这些工作组 (WG) 包括 CP 成人工作组、CP 儿科工作组、DM PDAC WG 和 Type3C DM WG。由 CP 成人工作组组织的 PROCEED 队列将 最终包括 1600 名成年受试者，重点关注患有急性、急性复发、 和慢性胰腺炎。由 CP 儿科工作组组织的 INSPIRRE 2 队列将 包括 860 名患有急性复发性和慢性胰腺炎的儿童。检测队列， 由 Type3C DM WG 组织，正在招募患有典型 2 型糖尿病的受试者作为 以及因胰腺癌或慢性胰腺炎而患有糖尿病的患者，以确定 这些类型的糖尿病之间的机制差异，并利用该信息 生物标志物和治疗益处。每个队列将代表大量深度样本 表型和特征化的受试者，具有全面注释的生物样本（生物 样本、射线照相）收集，并随着时间的推移对其进行跟踪。这些群体，当完全 招募和跟进，提供独特而强大的资源来解决许多问题 未解答的临床问题并解决 CPDPC 章程的目标。 CPDPC 是 组织起来允许大量辅助研究与主要队列并行进行 招募，这些辅助研究现在数量超过 50 项。这些辅助研究 帮助为 CPDPC 的工作提供信息，并建立了一套方法和协议 指导联盟，并为未来的临床提供明确的方法和定义 对这些疾病的研究。 CPDPC 的结构提供了无与伦比的机会 进行内部和外部合作，以促进临床研究并开发更有效的 复杂胰腺疾病的预测、预防和治疗。

项目成果

Biliary intervention rates during neoadjuvant therapy for adenocarcinoma of the pancreatic head.

胰头腺癌新辅助治疗期间的胆道干预率。

• DOI: 10.1016/j.hpb.2020.11.1147
• 发表时间: 2021
• 期刊: HPB : the official journal of the International Hepato Pancreato Biliary Association
• 作者: Kirkpatrick,Stacey;Gillies,Gwendolyn;Underwood,Patrick;Cioffi,Jessica;Trevino,JoseG;Hughes,StevenJ
• 通讯作者: Hughes,StevenJ

The oral microbiome, pancreatic cancer and human diversity in the age of precision medicine.

• DOI: 10.1186/s40168-022-01262-7
• 发表时间: 2022-06-15
• 期刊: MICROBIOME
• 影响因子: 15.5
• 作者: Herremans, Kelly M.;Riner, Andrea N.;Cameron, Miles E.;McKinley, Kelley L.;Triplett, Eric W.;Hughes, Steven J.;Trevino, Jose G.
• 通讯作者: Trevino, Jose G.

From tumor microenvironment communicants to biomarker discovery: Selectively packaged extracellular vesicular cargoes in pancreatic cancer.

• DOI: 10.1016/j.cytogfr.2020.01.001
• 发表时间: 2020-03
• 期刊: Cytokine & growth factor reviews
• 影响因子: 13
• 作者: Han S;Underwood P;Hughes SJ
• 通讯作者: Hughes SJ

Viscoelastic properties of human pancreatic tumors and in vitro constructs to mimic mechanical properties.

• DOI: 10.1016/j.actbio.2017.11.037
• 发表时间: 2018-03
• 期刊: Acta biomaterialia
• 影响因子: 9.7
• 作者: Rubiano A;Delitto D;Han S;Gerber M;Galitz C;Trevino J;Thomas RM;Hughes SJ;Simmons CS
• 通讯作者: Simmons CS

Update on the diagnosis and management of exocrine pancreatic insufficiency.

• DOI: 10.12688/f1000research.20779.1
• 发表时间: 2019-01-01
• 期刊: F1000Research
• 作者: Perbtani, Yaseen;Forsmark, Chris E
• 通讯作者: Forsmark, Chris E